title: Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry.
abstract: Lutetium-177 ((177)Lu) is a rare earth metal in the lanthanides series which decays by beta emission with a half life of 6.647 days to three excited states and the ground state of (177)Hf. When (177)Lu is produced by neutron capture in (176)Lu, inevitably an admixture is formed of the long-lived isomer (177)mLu. As its half-life of 160.4 days is so much longer than that of (177)Lu, concerns are raised on its possible enhancement in radiation dose to the patient treated with (177)Lu-DOTA-octreotate. This report evaluates this possible enhancement of the absorbed dose, based on the published pharmacokinetic profile of (177)Lu-DOTA-octreotate and assuming an admixture of 1 kBq (177)mLu /MBq (177)Lu (0.1%).
authors.affiliation: Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. m.konijnenberg@erasmusmc.nl.
authors.forename: Mark W
authors.initials: MW
authors.lastname: Konijnenberg
mesh_terms: D006207:Half-Life; D006801:Humans; D008187:Lutetium / Q000737:chemistry* / Q000493:pharmacokinetics; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D011868:Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics
chemical_list: D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D008187:Lutetium; C447941:lutetium Lu 177 dotatate; D015282:Octreotide